(Q38756298)

6 September 2017

title

Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives (English)

1 reference

6 September 2017

0 references

Archana Bhaw-Luximon

1

1 reference

6 September 2017

Dhanjay Jhurry

series ordinal

2

1 reference

6 September 2017

publication date

16 February 2017

1 reference

Cancer Chemotherapy and Pharmacology

6 September 2017

published in

1 reference

6 September 2017

volume

79

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

451-466

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-017-3251-7

6 September 2017

exact match

0 references

cites work

The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Anticancer Effect of AntiMalarial Artemisinin Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Case report of a pituitary macroadenoma treated with artemether

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinins target the SERCA of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Anticancer properties of distinct antimalarial drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

How Taxol/paclitaxel kills cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Antimalarial dihydroartemisinin also inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

The molecular mechanism of action of artemisinin--the debate continues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Ferroptosis: process and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Anti-cancer activity of DHA on gastric cancer--an in vitro and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Hypoxia modulates the effect of dihydroartemisinin on endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

The Antimalaria Agent Artemisinin Exerts Antiangiogenic Effects in Mouse Embryonic Stem Cell-Derived Embryoid Bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces necrotic cell death in schwannoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin is an inhibitor of ovarian cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/β-catenin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Therapeutic effects of dihydroartemisinin and transferrin against glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Reactive oxygen species in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

ROS function in redox signaling and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Anticancer activities of artemisinin and its bioactive derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Development of artemisinin compounds for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Study of artemisinin nanocapsules as anticancer drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Enhanced dissolution and stability of artemisinin by nano-confinement in ordered mesoporous SBA-15 particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Biodegradable Core-Shell Copolymer-Phospholipid Nanoparticles for Combination Chemotherapy: An In Vitro Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Stereochemistry-dependent cytotoxicity of some artemisinin derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

The interplay of immunotherapy and chemotherapy: harnessing potential synergies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Tumor necrosis factor and cancer, buddies or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Neutrophils in cancer: neutral no more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Immune cell promotion of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Suppression, subversion and escape: the role of regulatory T cells in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Effect of artesunate on immune cells in ret-transgenic mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Immunotherapy of autoimmunity and cancer: the penalty for success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

A review of the application of inflammatory biomarkers in epidemiologic cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3251-7

10.1007/S00280-017-3251-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1083845558

0 references

1 reference